XRD-0394 is under clinical development by XRad Therapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how XRD-0394’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
XRD-0394 is under development for the treatment of metastatic, locally advanced solid tumors or recurrent cancer. It is administered through oral route and acts by targeting ataxia telangiectasia mutated kinase (ATM) and deoxyribonucleic acid (DNA)-dependent protein kinase (DNA-PK).
XRad Therapeutics overview
XRad Therapeutics, Inc. operates in the healthcare industry focusing on biotechnology business.
For a complete picture of XRD-0394’s drug-specific PTSR and LoA scores, buy the report here.